ERBB2 and breast carcinoma: According to the Surveillance, Epidemiology, and End Results (SEER) registries for 5-year breast cancer-specific survival, TNBC is in the fourth position with 76.9% vs 94%, 90%, and 84% for Luminal A, Luminal B, and HER2+, respectively (Graph 8).